Resumo

GARCIA-LUQUE, A; SILVA-CUEVAS, MA; GRANDA-LOBATO, P  e  CORREA-PEREZ, A. Positive assessment of drugs: July, September and October of 2022. Sanid. Mil. [online]. 2022, vol.78, n.4, pp.261-267.  Epub 26-Jun-2023. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-857120220004000010.

SUMMARY: The drugs assessed by the European Medicines Agency made public in July, September and October of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Abaloparatida (Eladynos®); Espesolimab (Spevigo®); Faricimab (Vabysmo®); Fosdenopterina (Nulibry®); Gozetotida (Locametz®); Loncastuximab tesirina (Zynlonta®); Maralixibat (Livmarli®); Maribavir (Livtencity®); Mitapivat (Pyrukynd®); Nirsevibab (Beyforuts®); Nivolumab/Relatlimab (Opdualag®); Sutimlimab (Enjaymo®); Tabelecleucel (Ebvallo®); Teclistamab (Tecvayli®); Tezepelumab (Tezspire®); Tirzepatida (Mounjaro®); Vacuna tetravalente contra el dengue (Qdenga ®); Vipivotida tetraxetan lutecio (¹⁷⁷LU) (Pluvicto®); Voclosporina (Lupkynis®); Vutrisiran (Amvuttra ®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )